XML 58 R21.htm IDEA: XBRL DOCUMENT

Subsequent Event	6 Months Ended
Subsequent Event	Jun. 30, 2015
Subsequent Events [Abstract]
Subsequent Event	Subsequent Event In August 2015, we entered into a CodeEvolver^® platform technology license agreement with Merck. Under the terms of the agreement, we granted Merck a non-exclusive license to use our proprietary CodeEvolver^® protein engineering platform technology to develop novel enzymes for use in the manufacture of Merck's pharmaceutical products. We are eligible to receive up to $18 million over approximately the next 15 to 24 months, $5 million of which was paid upon the signing of the agreement and an additional $13 million subject to the satisfactory completion of certain technology transfer milestones. We will also be eligible to receive payments of up to a maximum of $15 million for each active pharmaceutical ingredient using novel enzymes developed by Merck using the CodeEvolver^® technology and used for commercial manufacturing purposes.